- Home
- MIRA
as 04-23-2025 4:00pm EST
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 20.5M | IPO Year: | 2023 |
| Target Price: | $14.00 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $5.01 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MIRA Pharmaceuticals Inc. News
MIRA Breaking Stock News: Dive into MIRA Ticker-Specific Updates for Smart Investing
ACCESS Newswire
12 hours ago
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
MT Newswires
7 days ago
Mira Says Diabetes Treatment Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms in Animal Model
ACCESS Newswire
8 days ago
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Benzinga
8 days ago
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
Zacks Small Cap Research
8 days ago
MIRA Continues Positive Testing Run
TipRanks
21 days ago
Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2
ACCESS Newswire
23 days ago
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Zacks Small Cap Research
23 days ago
MIRA Enrolls Patients Amid Rapid Progress
Compare MIRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRA MIRA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.